Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
How to see the Ursids, the final meteor shower of 2025 - 2Iranian-backed militias escalate in Iraq, targeting Kurdistan Region president Nechirvan Barzani
- 3Pick Your Favored method of transportation
- 4Vote in favor of Your #1 Home Exercise Gear: Execution and Comfort Matter
- 5Vote in favor of Your Number one Smartwatch: Exactness and Style Matter
- The Best Internet based Retailers for Style and Frill
- Mystery foot suggests a second early human relative lived alongside Lucy
- Explainer-What Novo Nordisk's weight-loss pill approval means for company, patients
- 6 Top of the line Lodgings All over The Planet, Which One Do You Concur With
- Dave Coulier reveals he has tongue cancer, his 2nd diagnosis in a year, after beating non-Hodgkin lymphoma
- Rescuers again fail to free whale stranded on Germany's Baltic coast
- New heart disease calculator predicts 30-year risk for young adults
- The Most Enrapturing Authentic Milestones to Visit
- Fuel Price Spike Drives Surge in Used EV Sales in Europe
